Redeye: aXichem - Essential approvals ahead
Redeye decreases its fair value range for aXichem after reviewing the case and making significant changes to our financial estimates to apply a more realistic outlook for the coming years. Despite our lowered base case of SEK24 (57), we emphasize +68% upside from current levels and see aXichem’s most important milestone (regulatory approval) on the horizon. We thus believe sales should finally ignite shortly afterward.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.